source
- Gilead wins legal battle over HIV drug as Eli Lilly opens early access program for obesity therapy retatrutideGilead Sciences secured a court victory concerning one of its HIV medicines, according to the brief report. The ruling resolves a legal dispute that had been pending, allowing the company to contin…
- Merck’s anti‑TL1A antibody tulisokibart fails Phase 2b in systemic sclerosis lung disease but succeeds in hidradenitis suppurativaMerck reported mixed Phase 2b results for its anti‑TL1A monoclonal antibody tulisokibart, acquired in the 2023 Prometheus Biosciences purchase. In patients with systemic sclerosis‑associated inter…BioSpace · 9d agoNegative readoutNeutral